Merck
CN
  • Comparison of therapeutic lipid target achievements among high-risk patients in Oman.

Comparison of therapeutic lipid target achievements among high-risk patients in Oman.

Angiology (2013-04-09)
Khalid Al-Waili, Ibrahim Al-Zakwani, Tamima Al-Dughaishi, Yajnavalka Baneerje, Hilal Al-Sabti, Khamis Al-Hashmi, Hatem Farhan, Khadija Al Habsi, Ali T Al-Hinai, Khalid Al-Rasadi
摘要

We compared therapeutic lipid target achievements among patients with diabetes or coronary heart disease (CHD) in Oman. A retrospective chart review of 94 patients was conducted at an outpatient clinic in Sultan Qaboos University Hospital, Muscat, Oman. The variables included low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and apolipoprotein B (apo B). The overall mean age of the cohort was 59 ± 12 years, 54% were male, 66% were diabetic, 48% hypertensive, 45% had CHD, 94% were on simvastatin, 4% were on fenofibrate, and 2% were on both simvastatin and fenofibrate. Lipid goal attainments of calculated LDL-C (<2.6 mmol/L), apo B (<0.9 g/L), and non-HDL-C (<3.36 mmol/L) were reached in 52%, 39%, and 53% of the patients, respectively. A significant proportion of high-risk patients treated with lipid-lowering agents reach LDL-C but not the apo B treatment targets, suggesting that the use of apo B target values should also be considered.

材料
货号
品牌
产品描述

Sigma-Aldrich
辛伐他汀, ≥97% (HPLC), solid
Supelco
辛伐他汀, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
非诺贝特, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
非诺贝特, ≥99%, powder
USP
非诺贝特, United States Pharmacopeia (USP) Reference Standard
USP
辛伐他汀, United States Pharmacopeia (USP) Reference Standard
辛伐他汀, European Pharmacopoeia (EP) Reference Standard
非诺贝特, European Pharmacopoeia (EP) Reference Standard
Supelco
辛伐他汀, analytical standard